

Readopt with amendments Nat 406, effective 5-17-17 (Document #12176), to read as follows:

PART Nat 406 **FORMULARY ONGOING REQUIREMENTS**

Nat 406.01 Formulary. Pursuant to RSA 328-E:16, III, the formulary for licensees shall be as follows:

(a) Amino acids **and peptides**; ~~including but not limited to:~~

~~(1) Acetyl Carnitine;~~

~~(2) EDTA;~~

~~(3) GABA;~~

~~(4) Glutathione;~~

~~(5) Levocarnitine;~~

~~(6) Succinic Acid (DMSA); and~~

~~(7) Tryptophan;~~

(b) Animal preparations and their derivatives, including but not limited to:

(1) Adrenal;

(2) Thymus; ~~and~~

(3) Thyroid;

(4) Fish Oils, including derived Omega-3 fatty acids such as Ethyl eicosapentaenoic acid, docosahexaenoic acid, and Omega-3 carboxylic acids;

(5) Hyaluronic acid; and

(6) Bile acids; including deoxycholic acid;

(c) The following antigout agents:

(1) Allopurinol;

(2) Colchicine; and

(3) Probenecid;

(d) ~~The following antihistamines:~~ **H₁ and H₂ antihistamine-class agents;**

~~(1) First generation, ethanolamine (aminoalkyl ether) Diphenhydramine; and~~

~~(2) First generation, piperazine-derived Meclizine;~~

(e) **The following anti-leukotriene agents:**

(1) Montelukast; and

(2) **Zafirlukast;**

(fe) The following anti-hyperglycemic agents:

(1) The alpha glucosidase inhibitor Acarbose;

(2) The biguanide Metformin; ~~and~~

(3) **Sulfonylurea-class agents;**

(4) **Thiazolidinedione-class agents (TZDs);**

(5) **Sodium-glucose transport protein 2 (SGLT-2) inhibitors;**

(6) **Dipeptidyl peptidase 4 (DPP-4) inhibitors;**

(7) **Glucagon-like peptide-1 (GLP-1) receptor agonists; and**

(3) Synthetic and human insulin;

(gf) The following anti-infective agents:

(1) The following antibacterial agents:

a. **The following a**Aminoglycosides, ~~including but not limited to:~~

1. Gentamicin;

2. Kanamycin sulfate; and

3. Tobramycin;

b. The following beta-lactam antibiotics:

1. **The following c**Cephalosporins, ~~including but not limited to:~~

(i) Cefaclor;

(ii) Cefadroxil;

(iii) Cefdinir;

(iv) Ceditoren;

(v) Cefibuten;

(vi) Cefixime;

(vii) Cefonicid sodium;

(viii) Cepodoxime proxetil;

(ix) Cefprozil;

(x) Ceftibuten;

(xi) Cefuroxime;

(xii) Cephalexin; and

(xiii) Cephradine;

2. **The following pPenicillins, including but not limited to:**

(i) Amoxicillin and clavulanate;

(ii) Amoxicillin;

(iii) Ampicillin and sulbactam;

(iv) Ampicillin;

(v) Bacampicillin;

(vi) Cloxacillin;

(vii) Dicloxacillin;

(viii) Oxacillin; and

(ix) Penicillin;

c. **The following Macrolides and ketolides, including but not limited to:**

1. Azithromycin;

2. Clarithromycin;

3. Dirithromycin;

4. Erythromycins;

5. Telithromycin; and

6. Troleandomycin;

d. **The following qQuinolones, including but not limited to fluoroquinolones;**

1. Ciprofloxacin;

2. Levofloxacin; and

3. Ofloxacin;

e. The following sulfonamides:

1. Sulfonamide;

2. Sofamethoxazole;

2. Trimethoprim; and

3. ~~Sulfones~~**Dapsone;**

f. **The following tTetracyclines, including but not limited to:**

1. Demeclocycline hydrochloride;
2. Doxycycline;
3. Minocycline;
4. Oxytetracycline; and
5. Tetracycline;

g. The following miscellaneous antibacterials:

1. Bacitracin;
2. Clindamycin;
3. Colistimethate;
4. Lincomycin;
5. Novobiocin;
6. Polymyxin B Sulfate;
7. Spectinomycin; ~~and~~
8. Vancomycin;

9. Daptomycin.

(2) ~~The following a~~Antifungals, ~~such as:~~

- a. Polyene;
- b. Amphotericin B;
- c. Nystatin;
- d. Fluconazole;
- e. Ketoconazole;
- f. Clotrimazole;
- g. Terbinafine; and
- h. Itraconazole;

(3) The following anti-virals:

- a. Valacyclovir;
- b. Acyclovir; ~~and~~
- c. Famciclovir; ~~and~~
- d. Oseltamivir;**

- (4) ~~The following anti-helminthics, such as:~~
- a. Mebendazole;
 - b. Thiabendazole;
 - c. Nitazoxanide;
 - d. Albendazole;
 - e. Ivermectin; **and**
 - ~~f. Mebendazole; and~~
 - fg.** Praziquantel;
- (5) The following antitubercular and antimycobacterial agents:
- a. **A**minosalicylic acid;
 - b. Cycloserine;
 - c. Pyrazinamidel
 - d. Rifabutin; and
 - e. Rifampin;
- (6) The following antiprotozoal and antiparasitic agents:
- a. The halogenated 8-hydroxyquinoline iodoquinol;
 - b. The following nitroimidazoles:
 1. Metronidazole; and
 2. Tinidazole;
 - c. The following quinolines:
 1. Chloroquine;
 2. Hydroxychloroquine;
 3. Mefloquine; and
 4. Quinine sulfate; and
 - d. The hydroxynaphthoquinone atovaquone;
- (7) The following miscellaneous anti-infective agents:
- ~~a. Immune globulins;~~
 - ab.** Mupirocin;
 - bc.** Permethrin; and
 - cd.** Pyrethrins;

(hg) The following anti-thyroid agent thionamides (thioureylenes) :

- (1) Methimazole; and
- (2) Propylthiouracil;

(ih) The following autonomic **drugsagents**:

(1) The following **anti**cholinergic agents:

a. The following antimuscarinic agents:

1. Atropine;
2. Atropine sulfate;
3. Belladonna;
4. Flavoxate;
5. Homatropine hydrobromide;
6. Hyoscyamine;
7. Methscopolamine; and
8. Scopolamine;

b. The muscarinic receptor agonist (~~cholinomimetic~~) pilocarpine;:

c. Nicotinic receptor agonists:

1. Nicotine; and

2. Varenicline;

d. The following acetylcholinesterase inhibitors:

1. Donepezil;

2. Galantamine; and

3. Rivastigmine;

(2) The following ergot derivatives:

- a. Ergonovine maleate; and
- b. Methergine;

(3) The following sympathomimetics:

- a. Ephedrine;
- b. Epinephrine, including autoinject forms;

- c. Pseudoephedrine;
- d. **Midodrine; Albuterol; and**
- e. ~~Midodrine; Clonidine;~~
- f. Guanfacine;**
- g. Albuterol;**
- h. Formoterol; and**
- i. Salmeterol;**

(4) The following sympatholytic agents, ~~also known as adrenergic blocking agents:~~

a. The following alpha adrenergic blocking agents:

- 1. Yohimbine; and
- 2. Tamulosin; and

b. **The following β adrenergic blocking agents;** ~~including but not limited to propranolol; and~~

- 1. Atenolol;**
- 2. Bisoprolol;**
- 3. Metoprolol;**
- 4. Propranolol; and**
- 5. Timolol;**

(5) ~~Nicotine;~~ **Agents for ADHD/Narcolepsy treatment:**

- a. Methylphenidate;**
- b. Dexmethylphenidate;**
- c. Amphetamine/dextroamphetamine;**
- d. Dextroamphetamine;**
- e. Lisdexamfetamine;**
- f. Atomoxetine; and**
- g. Modafinil;**

~~(i) The following barrier contraceptives:~~

~~(1) Cervical caps; and~~

~~(2) Diaphragms, excluding intrauterine devices;~~

(j) The following biologicals:

(1) The following biological response modifiers:

- a. Candida and trichophyton extracts; **and**
- b. Rho(D) immune globulins;
- ~~c. Skin test antigens; and~~
- ~~d. Tuberculin tests;~~

(2) Skin test antigens:

- a. Purified protein derivative tuberculin tests;**
- b. Candida albicans skin test antigen; and**
- c. Coccidioides immitis spherule derived skin test antigen;**

~~(32)~~ Blood typing serum;

(4) Blood and tissue derived products;

~~(53)~~ Enzymes, ~~including but not limited to:~~

- a. **Amylase;**
- b. Collagenase;
- ~~cb.~~ Desoxyribonuclease;
- ~~de.~~ Fribinolysin;
- ~~ed.~~ Hyaluronidase;
- f. Lipase;**
- ~~ge.~~ Pancrelipase; and
- f. Papain;

~~(64)~~ Electrolytes and fluid replacements, ~~including but not limited to:~~

- a. Saline solutions;
- b. Sterile water;
- c. D5W;
- d. Lactated ringers solution; and
- e. Sodium bicarbonate;

~~(75)~~ Hormones as described in Nat 406.01 ~~(p)(+)~~;

~~(86)~~ Immune globulins, as described in Nat 406.01(f)(6)(a);

~~(97)~~ Prostaglandins and prostaglandin analogs, ~~including but not limited to:~~

- a. Alprostadi;l;
- b. Bimatoprost;
- c. Dinoprostone;
- d. Iloprost; and
- e. Misoprostal; ~~and~~

~~(108)~~ Botolinum toxin derivatives~~;~~;

- a. Onabotilinumtoxin A;**
- b. Abobotulinumtoxin A; and**
- c. Incobotilinumtoxin A;**

~~(k) The blood formation and coagulation agent heparin, including subcutaneous, sublingual, and heparin locks;~~

~~(kl)~~ Botanical **preparations, with the following exceptions;** ~~s, including but not limited to:~~

(1) The following botanicals shall be excluded from this formulary:

- a. Legend or controlled Digitalis species derivatives;**
- b. Legend or controlled Coca species derivatives;**
- c. Legend or controlled Vinca species derivatives;**
- d. Legend or controlled Taxus species derivatives;**
- e. Legend or controlled Rauwolfia species derivatives; and**
- f. Derivatives of Papaver somniferum unless otherwise specified;**

~~(1) Non legend or controlled vinca species derivatives, provided that:~~

~~a. The following botanicals shall be excluded from this formulary:~~

- ~~1. Digitalis;~~
- ~~2. Cocaine;~~
- ~~3. Legend or controlled Vinca species derivatives; and~~
- ~~4. The following Papaver somniferum derivatives:~~

~~(i) Morphine;~~

~~(ii) Opiates; and~~

~~(iii) Paclitaxel; and~~

~~(2) Codeine for cough;~~

~~(1m)~~ The following cardiovascular ~~drugs~~**agents**:

(1) The following antilipemics:

a. **The following** HMG CoA Reductase Inhibitors, ~~such as~~:

1. Atorvastatin;
2. Fluvastatin;
3. Lovastatin;
4. Pravastatin; and
5. Simvastatin;

b. Cholestyramine; and

c. Colesevelam;

(2) The following anti-angina, piperazine derivative, metabolism modifiers, or p-FOX Inhibitors;

a. Ranolazine; and

b. Trimetazidine;

(3) ~~Rauwolfia alkaloids;~~ **The following anti-angina nitrates:**

a. Nitroglycerin;

b. Isosorbide dinitrate; and

c. Isosorbide mononitrate;

(4) ~~ACE's and ARB's, including but not limited to:~~

~~a. Lisinopril; and~~

~~b. Valsartan;~~ **Dihydropyridine-class calcium channel blockers;**

(5) **The following non-dihydropyridine calcium channel blockers:**

a. Diltiazem; and

b. Verapamil;

(6) Angiotensin Converting Enzyme inhibitors;

(7) Angiotensin II Receptor Blockers;

(8) The following diuretics:

a. ~~HCTZ;~~ **and Chlorthalidone;**

b. **Hydrochlorothiazide;**

c. **Epleronone; and**

d. **Spironolactone;**

(9) The following anti-coagulant agents:

a. **Heparin (for in-office use);**

b. **Heparin flushes;**

c. **Warfarin;**

d. **Apixaban; and**

e. **Rivaroxaban;**

(10) The following central nervous system agents:

~~(1) Anticonvulsant agents that enhance gamma amino benzoic acid (GABA) activity, including but not limited to the following GABA analogs and analog derivatives:~~ **The following anticonvulsant and anti-peptic agents:**

a. **Gabapentin;**

b. ~~The nipeptic acid derivative tiagabine;~~ **and Tiagabine;**

c. ~~Pre~~**gabalin;**

d. **Carbamazepine;**

e. **Oxcarbazepine;**

f. **Lamotrigine; and**

g. **Toiramate;**

(2) The following antispasmodics:

a. **Baclofen;**

b. **Cyclobenzaprine;**

c. **Methocarbamol; and**

d. Tizanidine;

(32) The following psychotherapeutics:

a. The following anxiolytics, sedatives and hypnotics:

1. Benzodiazepines;

a. Alprozolam;

b. Chlordiazepoxide;

c. Clobazam;

d. Clonazepam;

e. Diazepam;

f. Lorazepam; and

g. Temazepam;

2. The following non-benzodiazepine sedative-hypnotic agents:

~~(a.i)~~ The imidazopyridine agent Zolpidem; ~~and~~

~~(b.ii)~~ The cyclopyrrolone agent Eszopiclone; ~~and~~

c. Suvorexant; and

d. Ramelteon;

3. The anti-manic agent Lithium; **and**

4. The anxiolytic Buspirone;

(4) Antidepressants for FDA approved age groups:

a. Selective serotonin reuptake inhibitors (SSRIs):

1. Citalopram;

2. Escitalopram;

3. Fluoxetine;

4. Paroxetine; and

5. Sertraline;

b. Serotonin-norepinephrine reuptake inhibitors (SNRIs):

1. Duloxetine;

2. Desvenlafaxine; and

3. Venlafaxine;

c. Tricyclic antidepressants (TCAs):

1. Amitriptyline;

2. Doxepin;

3. Imipramine;

4. Nortriptyline; and

5. Clomipramine;

~~b. SSRI's and SNRI's, for patients over 18 years of age, such as:~~

~~1. Prozac;~~

~~2. Zoloft;~~

~~3. Effexor;~~

~~4. Celexa;~~

~~5. Lexipro; and~~

~~6. Paxil;~~

~~(e) Triple dye, for use in childbirth preparations;~~

~~(nf)~~ The following erectile dysfunction agents:

(1) Tadalafil; and

(2) Sildenafil;

~~(0q)~~ Homeopathic preparations and their derivatives **including both sterile injectable and non-injectable dosage forms;**

~~(pf)~~ Hormones **such as**, ~~including but not limited to:~~

(1) Adrenal hormones, ~~such as:~~

a. Aldosterone;

~~b. Cortisone acetate;~~

~~b~~e. DHEA;

~~c~~d. Epinephrine;

~~e.~~ Hydrocortisone; and

d. Pregnenalone; and

e. Synthetic glucocorticoids such as:

1. Betamethasone;

2. Cortisone acetate;

3. Dexamethasone;

4. Triamcinolone; Triamcinolone acetonide;

5. Methylprednisolone; Prednisolone;

6. Prednisone; and

7. Hydrocortisone;

(2) Agents acting at estrogen receptors, such as:

a. Selective estrogen-receptor modulators (SERMs), and anti-estrogens or estrogen antagonists, ~~such as:~~

1. Clomiphene;

2. Tamoxifen;

3. Toremifene; and

4. Raloxifene; and

~~b. Agents with mixed activity at steroidal receptors, such as Tibolone;~~

(3) Gonadal hormones, ~~such as:~~

a. Conjugated estrogens;

b. Estrogen;

c. Estradiol;

d. Estriol;

e. Estrone;

f. Estropipate;

g. Ethinyl estradiol;

h. HCG;

i. ~~Quinestrol~~Progesterone;

j. Progesterone~~Quinestrol~~; and

k. Testosterone;

- (4) Thyroid hormones;
 - a. **Levothyroxine;**
 - b. **Liothyronine;**
 - c. **Natural desiccated thyroid hormones; and**
 - d. **Calcium;**
- (5) Pituitary hormones, ~~such as:~~
 - a. ACTH;
 - b. Growth hormones; and
 - c. Oxytocin; and
- ~~(6) Parathyroid hormones, such as calcitonin;~~
- ~~(67) Hormonal modifiers, such as dutasteride;~~
 - a. **Dutasteride;**
 - b. **Finasteride; and**
 - c. **Anastrozole;**
- (q) Antitussives:**
 - (1) Codeine for cough;**
 - (2) Guafenesin; and**
 - (3) Benzonatate;**
- (rs) Local anesthetics, ~~such as:~~including both injectable and non-injectable dosage form such as:**
 - (1) ~~The following amino esters, so long as they are not prescribed~~Amino esters for in-office use:**
 - a. Procaine;
 - b. Chlorprocaine;
 - c. Tetracaine; and
 - d. Benzocaine;
 - (2) ~~The following amino amides, so long as they are not prescribed~~Amino amides, for in-office use:**
 - a. Lidocaine, ~~including both injectable and non-injectable dosage forms;~~

- b. Mepivocaine;
- c. Bupivacaine;
- d. Levobupacaine; ~~also known as Chirocaine;~~
- e. Etidocaine; and
- f. Prilocaine;

(3) The following other topical anesthetics:

- a. The ketone Dyclonine, **for in-office useso long as it is not prescribed;**
- b. The ether Pramoxine; ~~and~~
- c. The skin refrigerant ethyl chloride, also known as chloroethane; **and**
- d. Topical lidocaine;**

(4) The methyl group donor betaine; ~~and~~

~~(5) The sclerosing agent laureth 4, also known as Polidocanol, hydroxyl polyethoxy dodecane, lauromacrogolum 400, so long as it is not prescribed;~~

(s) Anti-psoriatic agents for topical use only:

- (1) Dithranol (anthralin);**
- (2) Calcipotriene;**
- (3) Fluocinonide; and**
- (4) Tacrolimus;**

(t) Minerals, trace minerals, and their derivatives, such as super saturated potassium iodine (SSKI);

(u) The following miscellaneous agents:

- (1) ~~Bee venom;~~**Acamprosate;**
- (2) ~~DMPS;~~**Acetazolamide;**
- (3) ~~DMSO;~~**Bee venom;**
- (4) ~~Ethyl chloride spray;~~**Crofelemer;**
- (5) ~~Fluro-ethyl spray;~~**Cromolyn sodium;**
- (6) ~~Fluro-methane spray;~~**DMPS;**
- (7) ~~Hydrogen peroxide;~~**DMSO;**
- (8) ~~Hydrochloric acid;~~**Ethyl Chloride spray;**
- (9) ~~Naltrexone, up to 10 milligrams per dose;~~**Fluro-ethyl spray;**

- (10) ~~MSM;Fluro-methane spray;~~
 - (11) ~~Oxygen;Hydrogen peroxide;~~
 - (12) ~~Hydrochloric acid;Salicylic acid preparations, including but not limited to:~~
 - ~~a. Mesalamine; and~~
 - ~~b. Topical salicylic acid preparations; and~~
 - (13) ~~Urea;Methylsulfonylmethane;~~
 - (14) ~~Ondansetron;~~
 - (15) ~~Oxygen;~~
 - (16) ~~Ozone;~~
 - (17) ~~Poly-L-Lactic Acid and derivatives;~~
 - (18) ~~Salicylates, Propionic acid, and Acetic acid derivatives such as:~~
 - ~~a. Mesalamine;~~
 - ~~b. Topical salicylic acid preparations;~~
 - ~~c. Indomethacin;~~
 - ~~d. Ibuprofen;~~
 - ~~e. Naproxen;~~
 - ~~f. Ketorolac; and~~
 - ~~g. Diclofenac;~~
 - (19) ~~Urea;~~
- (v) ~~The following paraphernalia:~~**In-office medical equipment, medical devices, and therapeutic devices such as:**
- (1) ~~Needles;~~
 - (2) ~~Syringes;~~
 - (3) ~~IV Tubing; and~~
 - (4) ~~Filters;~~
 - (5) **The following barrier contraceptives:**
 - a. Cervical caps; and**

b. Diaphragms, excluding intrauterine devices;

(w) ~~The respiratory anti-inflammatory agent cromolyn sodium;~~ **Agents needed to carry out diagnostic tests or physiological function tests such as:**

- (1) Mannitol;**
- (2) Methacholine;**
- (3) Dexamethasone;**
- (4) Dyes and contrasts such as:**
 - a. Imaging contrasts;**
 - b. Methylene blue; and**
 - c. Triple dye;**

(x) Vaccinations, provided they are for use and not prescription, ~~including but not limited to:~~

- (1) BCG;
- (2) Cholera;
- (3) Diphtheria;
- (4) DPT;
- (5) Haemophilus b Conjugate;
- (6) Hepatitis A Virus;
- (7) Hepatitis B;
- (8) Influenza Virus;
- (9) Japanese Encephalitis Virus;
- (10) Measles Virus;
- (11) Mumps virus;
- (12) Pertussis;
- (13) Plague;
- (14) Pneumococcal;
- (15) Polio virus – inactivated;
- (16) Poliovirus – live oral;
- (17) Rabies;
- (18) Rubella;

- (19) Smallpox;
 - (20) Tetanus IG;
 - (21) Tetanus Toxoid;
 - (22) Typhoid;
 - (23) Varicella; and
 - (24) Yellow fever; and
- (y) All forms of prescription and non-prescription vitamin preparations and their derivatives, except for Isotretinoin.

(z) Anti-addictive agents:

- (1) Disulfiram;**
- (2) Naltrexone; and**
- (3) Naloxone.**

Appendix

Rule	Statute
Nat 406	RSA 328-E:16, III